在市场翘首企盼下，《商业健康保险创新药品目录（2025年）》（下称"商保创新药目录"）于日前出 炉，这是我国首版商保创新药目录，将于2026年1月1日在全国范围内正式实施。 记者了解到，首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、 戈谢病等罕见病治疗药品，还有社会关注度较高的阿尔茨海默病治疗药品，与基本医保形成较好的互补 衔接。 三是体现了基本医保与商业保险的保障边界，基本医保坚持"保基本"定位，主要考虑安全可靠、疗效确 切、靶点机理比较成熟的药品，商保则更偏重创新、前沿的药物。 国家医保局要求，积极推动商保创新药目录纳入商业健康保险保障范围。各地医保部门要会同有关部门 推动多层次医疗保障体系建设，积极支持普惠型商业健康保险发展，商保创新药目录推荐商业健康保 险、医疗互助等多层次医疗保障体系参考使用。 这无疑为商业健康险市场开拓了新的增长空间。国家金融监督管理总局数据显示，2025年前10个月，人 身险和财产险公司合计实现健康险保费收入8943亿元，同比增长2.3%。 对于保险业而言，业内人士指出，商保创新药目录的落地有助于推动健康险从同质化的医疗费用补偿向 对创新药的 ...

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025), which will be implemented nationwide starting January 1, 2026 [1][2] Group 1: National Basic Medical Insurance Drug Catalog - The updated National Medical Insurance Drug Catalog includes 114 new drugs, of which 50 are first-class innovative drugs [1] - A total of 29 drugs that are either not clinically available or can be better replaced by other medications have been removed from the catalog [1] - The total number of drugs in the catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] Group 2: Commercial Health Insurance Innovative Drug Catalog - The inaugural Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, which complement the basic medical insurance effectively [2] - This initiative lays the groundwork for the complementary development of commercial insurance and basic medical insurance, contributing to the establishment of a multi-tiered medical security system [2]

Core Viewpoint - The release of the first edition of the "Commercial Health Insurance Innovative Drug Directory" in China, which includes 19 drugs, is expected to drive innovation in commercial health insurance products and open up growth opportunities in the health insurance sector [1][2]. Group 1: Innovative Drug Directory - The directory will officially implement on January 1, featuring 19 drugs, including CAR-T for cancer treatment and drugs for rare diseases like neuroblastoma and Gaucher disease, as well as Alzheimer's disease [1]. - The directory emphasizes three characteristics: support for innovation, focus on key areas, and delineation of the boundary between basic medical insurance and commercial insurance [1][2]. Group 2: Growth Opportunities in Health Insurance - Despite a general increase in commercial health insurance premium income, growth has slowed, with premiums not exceeding 1 trillion yuan in the past three years. The innovative drug directory is seen as a means to unlock growth potential [2]. - Data from the Financial Regulatory Authority indicates that health insurance premium income reached 894.3 billion yuan in the first ten months of 2025, a year-on-year increase of 2.3% [2]. Group 3: Industry Transformation - The directory is expected to shift health insurance from homogeneous competition to differentiated innovation, allowing for more precise product design tailored to specific diseases and populations [2][3]. - The establishment of the directory is anticipated to encourage insurance companies to develop specialized insurance products and deepen the "insurance + specialty drug services + health management" ecosystem [2][3]. Group 4: Challenges and Recommendations - Challenges in product pricing, underwriting, and claims processing remain for commercial health insurance, necessitating improvements in data sharing mechanisms between basic medical insurance and commercial insurance [3]. - Industry experts suggest creating a multi-party data sharing platform to support precise pricing and exploring mechanisms like reinsurance and government risk-sharing to mitigate risks [3].

Core Insights - The article discusses the rapid expansion and challenges of "Hui Min Bao," a low-cost health insurance product in China that aims to alleviate high medical costs for families [1][5][9] Group 1: Product Overview - "Hui Min Bao" originated in Shenzhen in 2015 and has since spread to over a hundred cities, benefiting millions [3] - The product features low premiums, typically ranging from 50 to 300 yuan annually, and offers coverage amounts generally exceeding 400,000 yuan [3][4] - The insurance covers both reimbursable medical expenses and non-reimbursable costs, including high-cost medications and specific medical services [4] Group 2: Challenges and Risks - The insurance faces dual pressures of participation and renewal rates, compounded by adverse selection and moral hazard due to low entry barriers [5][6] - The unclear roles of government and insurance companies in the operational framework pose significant challenges, particularly regarding risk-sharing and governance [5][6][8] Group 3: Sustainability and Innovation - Experts emphasize the need for a balance between inclusivity and commercial sustainability, suggesting that product differentiation and targeted designs for specific demographics are essential [6][7] - The development of a resilient "Hui Min Bao+" ecosystem requires collaboration among policymakers, regulators, insurers, and third-party service providers [7][8] Group 4: Future Directions - The article highlights the importance of integrating technology, institutional frameworks, and market forces to enhance the effectiveness of "Hui Min Bao" as a public product [9]

Core Viewpoint - The release of the commercial health insurance innovative drug directory addresses the issue of "can it be used" at the hospital level, but the "last mile" between high-priced innovative drugs and patients remains unconnected. To achieve seamless transformation from "policy text" to "patient benefit," three key barriers must be crossed [1][3]. Group 1: Release of the Directory - On December 7, 2025, the National Healthcare Security Administration officially released the first version of the "Commercial Health Insurance Innovative Drug Directory," incorporating 19 high-clinical-value, high-cost innovative drugs into the commercial health insurance payment framework for the first time at the national level [2]. - The directory includes 14 anti-tumor drugs (including all 5 CAR-T therapies available in China), 2 rare disease drugs, and 2 Alzheimer's disease new drugs, aligning with the current claims data of commercial health insurance, where malignant tumors are the most prevalent and costly disease area [2]. Group 2: Policy Support and Challenges - The commercial health insurance innovative drug directory is supported by policies that exempt the listed drugs from self-payment rate assessments, collection of alternative monitored varieties, and DRG payment scope, addressing the challenges hospitals face in using innovative drugs under cost control pressures [3]. - Despite the directory solving the "can it be used" issue, the connection between high-priced innovative drugs and patients still needs to be established, requiring standardization and universalization of the directory [3][4]. Group 3: Standardization and Payment Collaboration - The current directory serves as a guiding list rather than a mandatory coverage requirement for commercial insurance products, necessitating the promotion of core drugs in the directory as standard configurations in commercial health insurance, especially in inclusive "benefit insurance" products [4]. - The basic medical insurance market can leverage its large insured population to negotiate lower drug prices, but the fragmented nature of the commercial health insurance market poses challenges in forming a cohesive payment force to negotiate with pharmaceutical companies [4]. Group 4: Service Integration and Patient Experience - An ideal multi-tiered payment system should achieve seamless integration and instant settlement among basic medical insurance, commercial insurance, and patient out-of-pocket expenses, which currently requires patients to prepay and navigate complex claims processes [5]. - Commercial insurance accounts for only 7.7% of the overall payment for innovative drugs, indicating significant growth potential. Bridging the "last mile" between the 19 innovative drugs in the directory and patients requires coordinated efforts from government and market forces [5].

Core Insights - The National Healthcare Security Administration (NHSA) has officially released the first version of the "Commercial Health Insurance Innovative Drug Directory," incorporating 19 high-value, expensive innovative drugs into the commercial health insurance payment framework for the first time [1][2] - The introduction of this directory marks a significant step in improving China's multi-tiered medical security system and transforming the role of commercial insurance [1] Group 1: Directory Overview - The directory includes 19 drugs, of which 14 are anti-tumor drugs (including all 5 CAR-T therapies available in China), 2 are rare disease medications, and 2 are new drugs for Alzheimer's disease [1] - The structure of the directory aligns closely with current claims data from commercial health insurance, as malignant tumors are the most prevalent and costly disease area in China [1] Group 2: Policy Support - The drugs listed in the commercial health insurance innovative drug directory are exempt from self-payment rate assessments, do not fall under centralized procurement monitoring, and are not included in the Diagnosis-Related Group (DRG) payment scope, referred to as the "three exclusions" policy [2] - This policy alleviates the challenges hospitals face in using innovative drugs amid pressures from centralized procurement and DRG payment reforms [2] Group 3: Implementation Challenges - The transition from policy text to patient benefits requires overcoming three key barriers: standardization and inclusivity of the directory, payment coordination and bargaining power, and service fluidity and one-stop experience [2][3][4] - The current directory serves as a guiding list rather than a mandatory coverage requirement for commercial insurance products, necessitating efforts to make core drugs standard features in commercial health insurance, especially in inclusive "benefit insurance" products [3] Group 4: Payment and Service Integration - The commercial health insurance market is fragmented, with varying funding levels and coverage across different regions, which raises uncertainties about its ability to negotiate effectively with pharmaceutical companies [3] - Establishing a regional or national commercial insurance procurement coordination mechanism is essential for negotiating better drug prices and conditions, ensuring financial sustainability of coverage plans [3][4] - The ideal multi-tiered payment system should enable seamless integration and immediate settlement among basic medical insurance, commercial insurance, and out-of-pocket expenses, which currently requires patients to prepay and navigate complex claims processes [4]

Core Insights - The release of the new drug directories marks a significant advancement in China's innovative drug security system, transitioning to a "basic medical insurance + commercial insurance" complementary model, which will notably reduce the medication burden for insured patients, especially those with cancer and rare diseases [3][13][20] - The total number of drugs in the national medical insurance directory has increased to 3,253, with 114 new drugs added and 29 drugs removed, including 19 high-priced innovative drugs included in the commercial insurance directory [3][20] Summary by Sections National Medical Insurance Directory - The 2025 National Medical Insurance Drug Directory includes 114 new drugs, with 111 being newly launched in the last five years, marking a historical high for innovative drugs [4][14] - The approval-to-coverage timeline for innovative drugs has been significantly shortened, exemplified by the rapid inclusion of the domestic targeted drug for triple-negative breast cancer, which was approved in November 2024 and will be available for clinical use by October 2025 [5][15] Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory aims to address the accessibility of high-priced innovative drugs that exceed the basic medical insurance's affordability [8][17] - This directory includes 19 drugs, featuring advanced therapies such as CAR-T cell therapy and treatments for Alzheimer's and rare diseases, with costs often reaching hundreds of thousands [17][18] Policy Innovations - The "three exclusions" policy allows drugs in the commercial insurance directory to be exempt from basic medical insurance self-payment rate indicators, centralized procurement monitoring, and disease-based payment ranges, encouraging the development of insurance products that cover these high-priced drugs [18][20] - The strict admission standards for the commercial insurance directory ensure that only drugs with high innovation and clinical value are included, with a success rate of 88.19% for negotiations, indicating a rigorous selection process [16][19] Overall Impact - The dual directory adjustment represents a milestone in China's healthcare system, establishing a multi-tiered medical security framework that combines basic insurance, commercial insurance, and medical assistance [10][20] - The adjustments aim to accelerate the inclusion of innovative drugs in basic medical insurance while creating conditions for more innovative drugs to enter the market, ultimately enhancing patient access to life-saving medications [20][21]

Core Insights - The National Healthcare Security Administration (NHSA) has released the 2025 National Medical Insurance Drug List, adding 114 new drugs, including 50 innovative drugs of Class A, and 19 drugs included in the first commercial insurance innovative drug list [1][4] Summary by Sections New Drug Additions - The 2025 National Medical Insurance Drug List primarily adds chemical drugs, with a rapid increase in biological products and some traditional Chinese medicine [1] - Out of the 114 new drugs, 112 were included through negotiation and bidding, while 2 were directly included from national procurement [1] - A total of 111 new drugs were approved in the last five years, with the number of Class A innovative drugs reaching a historical high of 50 [1] Financial Impact - As of October 2023, the NHSA has paid over 460 billion yuan for drugs under agreement, benefiting over 1 billion patients and driving related sales exceeding 670 billion yuan [2] - Basic medical insurance covers approximately 44% of the costs for innovative drugs, while commercial insurance covers about 7% [2] Evaluation and Selection Criteria - The selection process for new drugs has seen a low pass rate during expert reviews, with only 127 out of 311 drugs passing to the negotiation table this year [2] - Some drugs were not favored due to "involutionary innovation," where the clinical value does not significantly improve compared to existing drugs [3][4] - To be included in the list, drugs must meet at least one of three criteria: filling clinical gaps, superior efficacy, or better cost-effectiveness [4] Commercial Insurance Innovations - The newly introduced commercial health insurance innovative drug list emphasizes drug innovation and clinical value, with 19 out of 141 submitted drugs successfully negotiated for inclusion [5] - The drugs in the commercial insurance list include 9 Class A new drugs, addressing gaps in basic medical insurance coverage [5] Future Directions - The NHSA plans to continue annual adjustments to the drug list to meet evolving clinical needs and incorporate advancements in medical technology [6] - The focus will be on supporting domestic and innovative drugs, enhancing collaboration between commercial insurance and innovative pharmaceutical companies [6]

Core Insights - The release of the first "Commercial Health Insurance Innovative Drug Directory" marks a significant step in addressing the challenges faced by patients regarding access to life-saving medications and innovative drugs [2][4] - The directory includes 19 drugs, focusing on treatments for cancer, rare diseases, and Alzheimer's disease, thereby expanding the scope of commercial health insurance [1][2] Group 1: Significance of the Directory - The directory aims to fill the gap in healthcare coverage, addressing the long-standing issue of high-cost innovative drugs not being included in basic medical insurance [2][3] - It provides a dual insurance framework alongside basic medical insurance, enhancing the healthcare safety net for the population [2][3] Group 2: Impact on the Commercial Health Insurance Market - The directory serves as a "navigation map" for the transformation of the commercial health insurance market, helping insurers design new products and adjust coverage based on the characteristics of the listed drugs [3][4] - It clarifies the coverage scope for consumers, reducing ambiguity in innovative drug coverage and enhancing consumer trust in insurance products [3][4] Group 3: Implications for Pharmaceutical Companies - By including clinically valuable innovative drugs, the directory opens new market opportunities for pharmaceutical companies, encouraging increased investment in research and development [3][4] - The directory is expected to stabilize market expectations for innovative drug companies, addressing the challenges of high R&D costs and uncertain market returns [3][4] Group 4: Future Considerations - The implementation of the directory in January 2026 raises questions about the management of innovative drug usage and the prevention of excessive claims from unhealthy individuals [4] - Insurance companies will need to develop new risk assessment models and collaborate with hospitals and pharmaceutical companies to ensure the effective use of the directory [4]

Core Insights - The release of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, marks a significant step in building a multi-tiered medical security system and supporting the development of the innovative drug industry in China [1] Group 1: Medical Insurance Coverage Expansion - The adjusted National Medical Insurance Drug Catalog now includes a total of 3,253 drugs, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - The 2025 National Medical Insurance Drug Catalog includes drugs that fill gaps in basic medical insurance coverage for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions [2] - Notable companies like Innovent Biologics and Jiangsu Hengrui Medicine have multiple innovative products included in the 2025 catalog, covering various fields such as oncology and metabolic diseases [2] Group 2: Commercial Health Insurance Innovative Drug Catalog - The first edition of the Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, focusing on high-innovation treatments for conditions like cancer, rare diseases, and Alzheimer's disease [3] - The introduction of this catalog aims to provide a transitional solution for high-priced innovative drugs that cannot be included in the basic medical insurance catalog, ensuring patient access to necessary treatments [3] Group 3: Policy and Capital Resonance - Recent policies have increasingly supported innovative drugs and medical devices, with 835 new drugs added to the medical insurance payment scope over the past seven years, including 149 innovative drugs [4] - The introduction of the Commercial Health Insurance Innovative Drug Catalog is seen as a crucial measure to address payment challenges and promote a diversified payment system [4] - Companies are encouraged to focus on developing clinically valuable drugs, leveraging their strengths in innovation and manufacturing [4] Group 4: Industry Outlook - The pharmaceutical industry is expected to enter a new phase of policy stabilization, industrial upgrading, and internationalization over the next five years, with the potential for high industry prosperity [6]